VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT

Prior treatment

• 1\) Secondary transplant patients;
• 2\) Have a history of tumor and have received any treatment for this tumor in the past 3 years, except for superficial bladder cancer , basal cell or squamous cell carcinoma of the skin, cervical intraepithelial carcinoma (CIN) or prostate intraepithelial carcinoma (PIN);
• 7\) Transplantation from an unrelated donor;

Other illness

• 3\) Serological reactions of known HIV, active hepatitis B, and active hepatitis C virus positive or syphilis positive;
• 4\) Suffering from mental illness or other conditions and unable to cooperate with the requirements of research treatment and monitoring;

Lab values

• 6\) Active heart disease, definition One or more of the following:
  • Long QTc syndrome or QTc interval \>480ms;
  • Complete left bundle branch block, II or III degree atrioventricular block;
  • Need for drug treatment or History of severe arrhythmia with clinical symptoms;
  • New York Heart Association classification ≥ II;
  • Left ventricular ejection fraction less than 50%;
  • Myocardial infarction, unstable angina, severe myocardial infarction within 6 months before enrollment History of unstable ventricular arrhythmias or any other arrhythmias requiring treatment, clinically severe pericardial disease, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.

Other

• Subjects who meet any of the following criteria shall not be enrolled in this study:
• 5\) Pregnant patients or patients who cannot take appropriate contraceptive measures during treatment;
• 8\) Those deemed not suitable for enrollment by the researcher.

• Patients with AML confirmed by bone marrow morphology and morphological recurrence after allo-HSCT (proportion of bone marrow morphological blast cells ≥5%);
• Age ≥18 years and ≤65 years old, regardless of gender;
• Eastern Oncology The evaluation of physical status of the cooperative group (ECOG-PS) is 0-2 points;
• An informed consent form must be signed before the start of the research procedure, and the patient himself or his immediate family members must sign the informed consent form. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the condition, the legal guardian or the patient's immediate family member will sign the informed consent form.